Timmerman Report

The Timmerman Report is a subscription-based publication that operates independently, delivering timely and comprehensive news and analysis in the biotech sector. It caters to anyone interested in gaining insights into the latest developments in drug creation, diagnostics, genomics, and other medical technologies that are reshaping healthcare. My aim is to uncover true innovations, spot emerging trends, and highlight the key players and market dynamics at play. With over ten years of experience covering the industry—including navigating through two downturns and one and a half growth periods—I provide context to stories that few others can offer. Readers can expect a broad perspective along with a consistent flow of news, in-depth features, and original insights. This thorough reporting can equip you for important meetings, help you find collaborators, seize investment opportunities, recruit promising talent, build relationships with colleagues, or even secure a job. I strive to write in a way that is accessible to everyone: offering insights that specialized readers will appreciate while also being understandable for those who are new to the topic. It’s the kind of clear, insightful journalism that remains relevant and valuable over time.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#820824

United States

#233374

Health/Biotechnology and Pharmaceuticals

#210

Traffic sources

Monthly visitors

Articles

FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround

2 weeks ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
What US Biotech Can Do to Meet the Moment

2 weeks ago | timmermanreport.com | David Li |Luke Timmerman

We have entered a new era in biotech. Turmoil at the FDA has introduced new uncertainty. NIH funding cuts and grant delays have led to academic institutions to hold off on job offers to young scientists. The Trump Administration’s reset of trade relations with the world caused a financial market meltdown, and wild rebound. All of these things are contributing factors making the biotech downturn longer and more intense than almost anybody imagined.
We Need an mRNA Champion in a Red Cape

2 weeks ago | timmermanreport.com | Larry Corey |Luke Timmerman

I grew up in an era of Superman comic books. Superman captivated the imagination of a generation of kids like me. It told stories of an otherwise ordinary human who could achieve extraordinary feats of speed and strength, leaping tall buildings with a single bound, to defeat the bad guys. Miracles could happen on a foundation of truth and justice, and that this was “the American way.”Superman, of course, was a work of fiction. Kryptonite isn’t in the periodic table.
Meet the Timmerman Traverse for Life Science Cares 2025 Team

2 weeks ago | timmermanreport.com | Luke Timmerman

The 5th annual Timmerman Traverse for Life Science Cares is fired up and ready for outdoor adventure in 2025. We’re on a mission to raise $1 million to fight poverty. This year’s team is preparing for a pair of challenging hikes in the Pacific Northwest, Aug. 18-19. We’ll cover 20 miles of trails, ascend 7,000 vertical feet, and savor some of the most spectacular scenery in North America. We’ll enjoy fresh air and exercise. We’ll make new friends. Together, we are giving back to our communities.
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune

3 weeks ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Timmerman Traverse for Damon Runyon Hits $700K Goal, Fueling Cancer Research

3 weeks ago | timmermanreport.com | Luke Timmerman

Times are tough in biotech, but this is an industry where we learn, adapt, and move forward. I’m proud to announce that the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit its fundraising goal of $700,000 to support high-risk / high-reward cancer research. We stand at $702,555 in closed donations. Our team of 16 hikers is now packing bags and gearing up to trek to Everest Base Camp at 17,500 feet / 5,364 meters. We will hike in Nepal Apr. 15-25.
Relationships That Make TechBio Go ‘Round: David Roblin on The Long Run

3 weeks ago | timmermanreport.com | Luke Timmerman

David Roblin is today’s guest on The Long Run podcast. David is the CEO of London-based Relation Therapeutics. The company uses multi-omic tools to look for drug targets in human tissue samples. It seeks to find the relationships between perturbed biological states and disease, with the help of machine learning.
GLP-1s Secret Weapon: Improving Health By Enhancing Agency

3 weeks ago | timmermanreport.com | Enhancing Agency |David Shaywitz |Luke Timmerman

The arrival of generative AI prompted many to worry about the adverse impact on human agency; after all, if the technology can effectively do what we’re doing, where does that leave us? This concern was the central focus of Reid Hoffman’s “Superagency,” which I reviewed for the WSJ earlier this year – see here. Essentially, Hoffman argues that new technologies can take some time to adjust to, but ultimately they empower us to do more things and greater things.
Longevity Is Having A Moment

3 weeks ago | timmermanreport.com | Enhancing Agency |David Shaywitz |Luke Timmerman

Dying, with few exceptions, has never been especially popular, and our shared interest in not dying hardly constitutes breaking news. Nevertheless, the aspiration of living longer — and remaining healthier while doing it — appears to be all the rage. Consider these recent headlines:“Why is longevity sudden so hot?” – Chrissy Farr, Second Opinion. “The longevity business is booming – and its scientist are clashing” – Amy Dockser Marcus, The Wall Street Journal.
Soleno Breaks Through, Tempero Takes On Addiction, and 23andMe Goes Bankrupt

4 weeks ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.